AVTX Chief Medical Officer Mittie Doyle Buys $12K of Stock
Avalo's Chief Medical Officer Mittie Doyle purchased 1,450 shares valued at $11,658.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc. ($AVTX), bought 1,450 shares at an average price of $8.04, worth about $11,658, on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $AVTX is up 3.6% after 1 week, down 0.4% after 1 month and down 36.8% to date (from the $17.83 close on Jun 23, 2026).
AVTX
Avalo Therapeutics, Inc.
Key Points
- Mittie Doyle, Avalo's Chief Medical Officer, bought 1,450 shares at $8.04 each on June 23, 2026.
- Shares of Avalo Therapeutics traded near $18.16 on Friday with a market cap of approximately $897.8 million.
- Analysts maintain a strong buy consensus for Avalo with a mean price target of $45.25.
Get $AVTX trade alerts by text
We text you when insiders, Congress or big funds trade $AVTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Avalo Therapeutics, Inc. alert may contain errors. Disclosures
On June 23, 2026, Mittie Doyle, the Chief Medical Officer of Avalo Therapeutics, Inc. (NasdaqCM: AVTX), bought 1,450 shares of the company's stock. The shares were purchased at an average price of $8.04, bringing the total transaction value to $11,658. This insider purchase was not part of a pre-planned trading program.
Insider Buying and Selling at Avalo Therapeutics, Inc.
Mittie Doyle's recent purchase is one of several insider transactions at Avalo Therapeutics. On the same day, Ron Philip bought 40,200 shares, while Jennifer Riley, the Chief Strategy Officer, and Christopher Ryan Sullivan, the Chief Financial Officer, sold 588 and 138 shares, respectively, on June 10, 2026.
Avalo Therapeutics, Inc. Stock Up 9.6%
Shares of Avalo Therapeutics traded near $18.16 on Friday. The biotechnology company has a market cap of about $897.8 million. Avalo's stock has a 52-week range between $4.50 and $24.27. The 50-day moving average is $15.44, while the 200-day moving average stands at $15.56. The company has a forward P/E ratio of -6.1, indicating it is not currently profitable, and a beta of 0.819.
Analysts Set New Price Targets
On June 12, 2026, B of A Securities initiated coverage on Avalo Therapeutics with a 'buy' rating and a price target of $35. Other firms like Citizens, Wedbush, and Mizuho have maintained their 'buy' ratings, with price targets ranging from $34 to $62. The consensus among 12 analysts is a 'strong buy' with a mean price target of $45.25.
About Avalo Therapeutics
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company based in Wayne, Pennsylvania. It focuses on developing treatments for immune-mediated inflammatory diseases. Its lead product, AVTX-009, is a monoclonal antibody targeting interleukin-1ß, which is in phase 2 trials for inflammatory diseases. The company, led by CEO Dr. Garry A. Neil, was initially known as Cerecor Inc. before rebranding in August 2021. Avalo employs around 33 people.
Bottom Line
Mittie Doyle's insider purchase reflects her confidence in Avalo Therapeutics, a company working on innovative treatments for inflammatory diseases. With a strong buy consensus from analysts and a robust pipeline, Avalo remains a company to watch. Investors should note that insider trading reports are backward-looking and may not represent current positions.
Related Filing Alerts
Source: Mittie Doyle's Form 4 filing on $AVTX (Jun 23, 2026). Find the original filing: AVTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts